MA48743A - Composés et méthodes de traitement d'infections bactériennes - Google Patents

Composés et méthodes de traitement d'infections bactériennes

Info

Publication number
MA48743A
MA48743A MA048743A MA48743A MA48743A MA 48743 A MA48743 A MA 48743A MA 048743 A MA048743 A MA 048743A MA 48743 A MA48743 A MA 48743A MA 48743 A MA48743 A MA 48743A
Authority
MA
Morocco
Prior art keywords
compounds
treatment
methods
bacterial infections
infections
Prior art date
Application number
MA048743A
Other languages
English (en)
Inventor
Janelle Comita-Prevoir
Thomas Francois Durand-Reville
Satenig Guler
Jan Romero
Mark Sylvester
Ruben Tommasi
Camilo Velez-Vega
Xiaoyun Wu
Jing Zhang
Original Assignee
Entasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Inc filed Critical Entasis Therapeutics Inc
Publication of MA48743A publication Critical patent/MA48743A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA048743A 2017-05-08 2018-05-08 Composés et méthodes de traitement d'infections bactériennes MA48743A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08

Publications (1)

Publication Number Publication Date
MA48743A true MA48743A (fr) 2020-04-08

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048743A MA48743A (fr) 2017-05-08 2018-05-08 Composés et méthodes de traitement d'infections bactériennes

Country Status (26)

Country Link
US (1) US11046694B2 (fr)
EP (1) EP3630111B1 (fr)
JP (1) JP7058322B2 (fr)
KR (1) KR102611447B1 (fr)
CN (1) CN110709081B (fr)
AU (1) AU2018266640B2 (fr)
CY (1) CY1125340T1 (fr)
DK (1) DK3630111T3 (fr)
EA (1) EA038393B1 (fr)
ES (1) ES2907858T3 (fr)
HR (1) HRP20220231T1 (fr)
HU (1) HUE057592T2 (fr)
IL (1) IL270380B (fr)
LT (1) LT3630111T (fr)
MA (1) MA48743A (fr)
MX (1) MX385203B (fr)
MY (1) MY201377A (fr)
PE (1) PE20200333A1 (fr)
PH (1) PH12019502509A1 (fr)
PL (1) PL3630111T3 (fr)
PT (1) PT3630111T (fr)
SG (1) SG11201909443YA (fr)
SI (1) SI3630111T1 (fr)
SM (1) SMT202200110T1 (fr)
TW (1) TWI791018B (fr)
WO (1) WO2018208769A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (fr) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones comme inhibiteurs de sérine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
CN122180683A (zh) * 2023-09-19 2026-06-09 恩塔西斯治疗公司 用于治疗细菌感染的化合物和方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (fr) 2008-06-19 2015-09-23 Astra Zeneca Holding France Utilisation de (1r, 2s, 5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy) -, sel monosodique en tant que réactif de diagnostic pour la détection de sérines bêta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
EP2768503A1 (fr) 2011-07-26 2014-08-27 Wockhardt Limited Compositions pharmaceutiques comprenant un antibiotique bêta-lactame, du sulbactam et un inhibiteur de bêta-lactamase
CA2842777C (fr) 2011-07-26 2015-12-29 Wockhardt Limited Compositions pharmaceutiques comprenant du sulbactam et un inhibiteur de beta-lactamase
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (fr) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Méthodes de traitement d'infections bactériennes
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
US8916709B2 (en) * 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ， インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
NZ706734A (en) 2012-09-03 2016-05-27 Wockhardt Ltd Pharmaceutical compositions useful for the treatment or control of bacterial infections
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (fr) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
SG11201901658PA (en) 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds

Also Published As

Publication number Publication date
CN110709081A (zh) 2020-01-17
DK3630111T3 (en) 2022-03-14
MY201377A (en) 2024-02-21
HUE057592T2 (hu) 2022-05-28
WO2018208769A1 (fr) 2018-11-15
AU2018266640B2 (en) 2022-03-03
KR20200005586A (ko) 2020-01-15
MX385203B (es) 2025-03-14
KR102611447B1 (ko) 2023-12-06
EA201992370A1 (ru) 2020-03-10
CY1125340T1 (el) 2024-02-16
JP7058322B2 (ja) 2022-04-21
PT3630111T (pt) 2022-03-01
PH12019502509A1 (en) 2020-07-13
LT3630111T (lt) 2022-03-10
TWI791018B (zh) 2023-02-01
EP3630111B1 (fr) 2021-11-24
IL270380B (en) 2022-06-01
PE20200333A1 (es) 2020-02-14
SG11201909443YA (en) 2019-11-28
SI3630111T1 (sl) 2022-05-31
CA3059773A1 (fr) 2018-11-15
BR112019023130A2 (pt) 2020-05-26
US11046694B2 (en) 2021-06-29
US20200165251A1 (en) 2020-05-28
JP2020519687A (ja) 2020-07-02
NZ758200A (en) 2025-12-19
PL3630111T3 (pl) 2022-05-23
EA038393B1 (ru) 2021-08-20
MX2019013291A (es) 2020-01-15
CN110709081B (zh) 2023-09-22
ES2907858T3 (es) 2022-04-26
HRP20220231T1 (hr) 2022-04-29
AU2018266640A1 (en) 2019-11-07
SMT202200110T1 (it) 2022-05-12
TW201843152A (zh) 2018-12-16
EP3630111A1 (fr) 2020-04-08

Similar Documents

Publication Publication Date Title
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
MA43811A (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
MA50267A (fr) Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3383857A4 (fr) Composés et méthodes de traitement d'infections bactériennes
EP3374350A4 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l'infection pare. coli
EP3775263A4 (fr) Compositions et méthodes de traitement de l'acné
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3600285A4 (fr) Compositions topiques et méthodes de traitement
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3641746A4 (fr) Méthodes et compositions pour le traitement d'une infection microbienne
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3655404A4 (fr) Composés et leur utilisation pour le traitement d'infections microbiennes
EP3840752A4 (fr) Méthodes de traitement de la myélofibrose indépendantes du nombre de plaquettes
EP3599983A4 (fr) Endoscopes et méthodes de traitement